Optimising patient selection
in early-stage lung cancer: evolving pathology practices and the MDT approach
Monday 24 June – 12:30 – 13:30
Monday 24 June – 12:30 – 13:30
Chair: Alexander Yarunin, AstraZeneca
Welcome and introduction
Alexander Yarunin, Director of Molecular Diagnostics at AstraZeneca
Molecular pathology in the setting of early-stage NSCLC: exploring contrasts in practice with advanced disease
Paul Hofman, Nice Sophia Antipolis University, France
Navigating diagnostic dilemmas in early-stage NSCLC: the MDT approach
Beatriz Bellosillo
Edurne Arriola Aperribay
Interactive discussion
Unlocking the Potential of NGS Clonality and MRD Testing: From Research to High-Throughput Environments
Tuesday 25 June – 9:45 – 10:45
Welcome and introduction
Parth Sitlani Invivoscribe
Beyond systematic memory B-cell archiving: Mining B-cell receptor repertoires for antigen-specific clones and tumor cell precursors
Dr. Artur Kibler, Institute of Cell Biology, University of Duisburg-Essen, Essen, Germany
Implementation of NGS-based clonality and MRD testing in a high throughput environment
Wayne Yu, Memorial Sloan Kettering Cancer Center, New York, NY, US
Q&A Session
From DNA to insights: Uncovering the overlooked in longitudinal cancer monitoring
Tuesday 25 June – 9:45 – 10:45
Optimizing Acute Myeloid Leukemia monitoring: A novel NGS application for Measurable Residual Disease (MRD) assessment
Silvia Salmoiraghi, PhD Biologist, Ultra-specialist Laboratory of Clinical Pathology-Hematology, ASST Papa Giovanni XXIII Hospital, Bergamo, Italy
Unlocking access to MSK-ACCESS®: A decentralized approach to innovative liquid biopsy technology
Chloe Ryder, PhD Product Manager – Liquid Biopsy, SOPHiA GENETICS, Rolle, Switzerland
From Detection to Action: Enhancing the Integrity of HRD Tests and Embracing ctDNA in Prostate Cancer
Tuesday 25 June – 13:00 – 14:00
Welcome and introductions
Eva Maria Ciruelos
Confidence and Competence: Ensuring Excellence in HRD Testing
Nicole Pfarr, TUM · Institut für Allgemeine Pathologie und Pathologische Anatomie
ctDNAin the Spotlight: Transforming the Landscape of Prostate Cancer Diagnostics
Umberto Malapelle, University of Naples Federico II | UNINA · Department of Public Health
Hot Topics –Variant Interpretation
Begoña Vieites
Discussion, Q&A and closing remarks
Eva Maria Ciruelos
Integrating ctDNA analysis for Targeted Therapy in Metastatic Breast Cancer
Tuesday 25 June – 13:00 – 14:00
Integrating ctDNA analysis for Targeted Therapy in Metastatic Breast Cancer
Dr. Pierre-Jean Lamy, Labosud-Ocbiologie, Imagenome, Montpellier, France
Sensitive Mutation Profiling in tissue and liquid biopsy: Detect clinically relevant biomarkers in difficult samples quickly and cost-effectively.
Dr. Alexander Sartori, Sr. Manager Scientific Affairs, Agena Bioscience
Why is comprehensive testing essential in cancer care?
Wednesday 26 June – 13:00 – 14:00
Welcome & PCC Overview
Kara O’Brien, Executive Director, Global Precision Diagnostics, Novartis
The overwhelming data in support of the use of comprehensive genomic testing to improve patient outcomes
Elena Castro, Medical Oncologist, Hospital 12 de Octubre, Madrid, Spain
Implementing comprehensive testing into routine practice
Fernando Lopez-Rios, Chief of Molecular Diagnostic, Service“12 de Octubre” University Hospital, Madrid, Spain
The role of tissue and liquid biopsy in comprehensive testing
Paul Hofman, Professor of Pathology and Head of the Laboratory of clinical and Experimental Pathology, Nice Sophia Antipolis University, France
Discussion, Q&A
Closing
Kara O’Brien, Executive Director, Global Precision Diagnostics, Novartis